Who
Jeff E. Knight
Chief Dev & Operating Officer
Company insider
Files Form 4 as: Chief Dev & Operating Officer, ALX Oncology Holdings; Chief Dev. & Operating Officer, Crinetics Pharmaceuticals.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $10.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Sep 2021
- Last trade
- 16 Apr 2026
- Last filed
- 17 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 17 Apr 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.2M49,474 at $23.98 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $193K9,624 at $20.02 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $380K19,336 at $19.64 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,474 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,624 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,336 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.4M85,163 at $40.10 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,474 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,624 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,336 at $0.00 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.2M49,474 at $23.98 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $193K9,624 at $20.02 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $380K19,336 at $19.64 | filing |
| 8 Apr 2026filed 10 Apr 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.4M85,163 at $40.10 | filing |
| 16 Mar 2026filed 18 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $221K5,950 at $37.11 | filing |
| 16 Mar 2026filed 18 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $150K3,961 at $37.77 | filing |
| 16 Mar 2026filed 18 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $221K5,950 at $37.11 | filing |
| 16 Mar 2026filed 18 Mar 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $150K3,961 at $37.77 | filing |
News
No headline names them, or the companies they trade most, lately.